Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Enveric Biosciences (NASDAQ:ENVB)
Ações da Enveric Biosciences disparam após divulgação de novos dados sobre candidato a medicamento principal
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals - Enveric Biosciences (NASDAQ:ENVB)